Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Recalcitrant Contact or Atopic Dermatitis
NCT00931242Phase 2Completed
- Sponsor
- Tufts Medical Center
- Start
- Jun 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in atopic dermatitis (AD) and allergic contact dermatitis (ACD), sponsored by Tufts Medical Center. Primary endpoint: Number of Patients Achieving an Improvement in Investigator Global Assessment by Two or More Points at 12 weeks. Started Jun 2009; status: completed.
02
Drugs
apremilast
03
Conditions
atopic dermatitis (AD)allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT00931242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931242.